Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

BioTheryX (United States) | Researchclopedia

Back to institutions

BioTheryX (United States)

Chappaqua, New Yorkcompany

31

Works

3,130

Citations

20

h-index

Top Research Topics

Protein Degradation and Inhibitors Multiple Myeloma Research and Treatments Acute Myeloid Leukemia Research

Top Researchers

Frank Mercurio Therapeutics Clinical Research

78 works15,176 citationsh-index: 38

Recent Research

Abstract PS4-06-04: First-in-human Phase 1 study of BTX-9341, a CDK4/6 bifunctional degrader, as monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer - first emerging data

A. Patnaik,M. Block,et al.

20260 citations

Ubiquitin and proteasome pathways

Advanced Breast Cancer Therapies

Cancer-related Molecular Pathways

Peptidase Inhibition and Analysis

Epigenetics and DNA Methylation

Angiogenesis and VEGF in Cancer

Hemoglobinopathies and Related Disorders

Dermatology and Skin Diseases

CRISPR and Genetic Engineering

130 works12,321 citationsh-index: 50

Maneesh Kumar Jawaharlal Nehru Technological University, Hyderabad

189 works6,935 citationsh-index: 45

Qiao Liu South China Agricultural University

242 works4,882 citationsh-index: 37

Steven Greene North Carolina State University

126 works3,762 citationsh-index: 28

Qiao Liu Shandong University

209 works3,718 citationsh-index: 31

Discovery of a PDE4B and PDE4D selective bifunctional degrader for management of chronic inflammatory disorders

Arvind Shakya,Qiao Liu,et al.

20251 citations

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML

Brian Ball,Wenbin Xiao,et al.

20253 citations

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML

Brian Ball,Wenbin Xiao,et al.

20240 citations

Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRAS- and RTK-driven cancers.

Kyle Begovich,Angela Schoolmeesters,et al.

20241 citations

Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.

Hannah Majeski,Kirti Chahal,et al.

20245 citations